Jim Cramer Says He Likes Drug Stocks Here As He Discusses Johnson & Johnson
Key takeaways
- Cramer mentioned the company while highlighting his current sentiment around drug stocks, as he remarked:
- Obviously, the other leadership groups are a little more palatable to me… Healthcare, eureka, I found it.
- Cramer mentioned the company’s “great new drug profits” during the June 5 episode, as he said:
Jim Cramer Says He Likes Drug Stocks Here As He Discusses Johnson & Johnson Syeda Seirut Javed Fri, June 12, 2026 at 9:45 PM GMT+7 2 min read JNJ KVUE Johnson & Johnson (NYSE:JNJ) was among the stocks Jim Cramer commented on, saying that tech stocks cannot be trusted to lead anymore. Cramer mentioned the company while highlighting his current sentiment around drug stocks, as he remarked:
Obviously, the other leadership groups are a little more palatable to me… Healthcare, eureka, I found it. This is the leadership group that we’ve been looking for. Take Johnson & Johnson. It’s been shedding slower-growing divisions like Kenvue, its consumer products business, as well as its commodity orthopedic operations, focusing on fast-growing drugs. I like that. It’s got a ton of them. It’s got an AAA balance sheet, better than the US government. I like the drug stocks here. I like the UnitedHealths here.
Johnson & Johnson (NYSE:JNJ) develops and sells healthcare products, including pharmaceuticals and medical technologies, with treatments in immunology, oncology, neuroscience, cardiovascular care, and infectious diseases. Cramer mentioned the company’s “great new drug profits” during the June 5 episode, as he said: